Daniel Movens has resigned as CEO of Detroit-based Caraco Pharmaceutical Laboratories Ltd. (NYSE Amex: CPD), several weeks after the Food and Drug Administration seized tainted drugs and ingredients and two class-action lawsuits were filed against the generic drug maker and Movens.
Daniel Movens resigns as CEO of Caraco Pharmaceutical
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.